BCMA — Drug Target

All drugs that target BCMA — marketed and clinical-stage. Includes 3 drug classes acting on this target.

Drug classes

CAR-T cell therapy · CAR T-cell therapy · Monoclonal antibody-drug conjugate

Marketed (1)

• Blenrep · GSK · Oncology
  Belantamab mafodotin binds to BCMA on multiple myeloma cells, is internalized, and releases a cytotoxic agent that disrupts microtubules, causing cell death.

Phase 2 pipeline (6)

• Cilta-cel OOS Therapy · Janssen Scientific Affairs, LLC · CAR-T cell therapy · Oncology
  Chimeric antigen receptor T-cell therapy
• Anitocabtagene autleucel · Kite, A Gilead Company · CAR T-cell therapy · Oncology
  Anitocabtagene autleucel is a chimeric antigen receptor (CAR) T-cell therapy that targets the B-cell maturation antigen (BCMA) on multiple myeloma cells.
• Belantamab mafodotin frozen liquid · GlaxoSmithKline · Monoclonal antibody-drug conjugate · Oncology
  Belantamab mafodotin is a monoclonal antibody-drug conjugate that targets BCMA.
• Human BCMA Targeted T Cells Injection · Hrain Biotechnology Co., Ltd. · CAR-T cell therapy · Oncology
  BCMA-targeted T cells
• BCMA CAR-T cells · Chongqing Precision Biotech Co., Ltd · CAR-T cell therapy · Oncology
  BCMA-targeting CAR-T cells
• Belantamab mafodotin lyophilized powder · GlaxoSmithKline · Monoclonal antibody-drug conjugate · Oncology
  Monoclonal antibody targeting BCMA